Press Releases | Medtronic

Month Year

Email alerts

May 7, 2019

Prospective Data Demonstrates Effective Pain Relief and Improved Function Using Medtronic's Evolve(SM) Workflow with Spinal Cord Stimulation

To Assess the Potential of Non-Opioid Treatment Options for Chronic Pain, Study Evaluates Pain Relief, Patient Function and Satisfaction

DUBLIN and LAS VEGAS - May 7, 2019 - Medtronic plc (NYSE:MDT) today announced primary endpoint (3-month) results of the Vectors Post Market Clinical Study that demonstrated effective pain relief...
Apr 30, 2019

Medtronic Announces U.S. Commercial Launch of Solitaire(TM) X Revascularization Device

System Offers New Options for Improving Outcomes in Treating Stroke; World's Second-Leading Cause of Death, Third-Leading Cause of Disability

DUBLIN - April 30, 2019 - Medtronic plc (NYSE:MDT) today announced the U.S. launch of the Solitaire(TM) X Revascularization Device - and its first use in patients for the treatment of acute...
Apr 8, 2019

New Study Finds Targeted Drug Delivery (TDD) is Associated with a Reduction in Health Care Utilization and Cost for Cancer Pain Patients

Savings Are Driven by Fewer Inpatient Visits, Shorter Inpatient Length of Stay, and Fewer Emergency Department Visits

DUBLIN - April 8, 2019 - Medtronic plc (NYSE:MDT) today announced results of a study published in JAMA Network Open that demonstrates a reduction in health care utilization and cost for cancer...
Feb 28, 2019

Medtronic Announces Approval and Launch of Japan's First DBM Bone Grafting Product for Spine and Orthopedic Procedures

Grafton(TM) DBM Product Will Provide More Options for Spine and Orthopedic Surgeons in Japan

DUBLIN and TOKYO - February 28, 2019 - Medtronic plc (NYSE:MDT) announced today the Japanese launch of the Grafton(TM) Demineralized Bone Matrix (DBM) bone grafting product for spine and...
Feb 27, 2019

Medtronic Announces FDA Clearance and U.S. Launch of the Accurian Radio Frequency System for Nerve Tissue Ablation

Medtronic Expands Pain Portfolio with Minimally Invasive Therapy to Support Patients Throughout the Care Continuum

DUBLIN - February 27, 2019 - Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Accurian(TM) RF ablation platform, which conducts radio...
Feb 20, 2019

Medtronic Announces U.S. Commercial Launch of Deep Brain Stimulation for Medically-Refractory Epilepsy

With Official Launch and First Implant, Several Health Insurers Now Consider DBS Therapy for Epilepsy a Covered Indication

DUBLIN - February 20, 2019 - Medtronic plc (NYSE:MDT) today announced both the U.S. launch of Deep Brain Stimulation (DBS) for medically-refractory epilepsy and the first commercially implanted...
Feb 20, 2019

Medtronic EVP & RTG President Geoff Martha to Speak at Leerink Partners Global Healthcare Conference

DUBLIN - February 20, 2019 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the 8th Annual Leerink Partners Global Healthcare Conference...
Feb 7, 2019

Medtronic Receives FDA Approval on Expanded Indication for Pipeline Flex Embolization Device

Approval Based on Clinical Data from the PREMIER Trial - New Indication Provides Options for Patients with Small or Medium, Wide-Necked Brain Aneurysms

DUBLIN - February 7, 2019 - Medtronic plc (NYSE:MDT) announced today that it has received U.S. Food and Drug Administration (FDA) approval on an expanded indication for its Pipeline(TM) Flex...
Jan 28, 2019

Medtronic Announces U.S. Commercial Launch of Mazor X Stealth(TM) Edition for Robotic-Assisted Spine Surgery

First U.S. Patients Treated Using Mazor X Stealth(TM) Edition at Norton Healthcare and Reston Hospital Center

DUBLIN - January 28, 2019 - Medtronic plc (NYSE:MDT) today announced the first U.S. patients treated with the Mazor X Stealth(TM) Edition for spine surgery following its recent commercial launch....
Jan 17, 2019

Medtronic Enrolls First Patient in Clinical Study to Assess Pain Control and Oral Opioid Elimination with Targeted Drug Delivery

Study Will Further Advance Understanding of Effectiveness and Tolerability of the SynchroMed(TM) II Intrathecal Drug Delivery System in Patients Who Have Weaned off Oral Opioids

DUBLIN - January 17, 2019 - Medtronic plc (NYSE:MDT) today announced the first patient enrolled in the Embrace TDD (targeted drug delivery) clinical study that will evaluate the use of the...

Show per page